相关实验视频

Updated: May 11, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

在脑瘤中应用EGFR-TKI,这是未来的突破?

Shiying Feng^1,2, Huiqin Liu³, Cuilan Yun³

¹Central Clinical Medical School, Baotou Medical College, Baotou, Inner Mongolia, 014040, China.

Journal of translational medicine

|April 16, 2025

概括

皮肤上生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 对治疗脑瘤,包括原发性瘤和转移,显示出有前途. 需要进一步的研究来克服抗药性等挑战,并改善患者的生存率.

科学领域:

神经瘤学神经瘤学
医学瘤学医学瘤学
药理学药理学是指药理学的学科.

背景情况:

主要和次要的大脑瘤存在显著的死亡率和有限的治疗选择.
创新策略对于治疗肺癌和乳腺癌中的质瘤,脑膜瘤和大脑转移至关重要.
表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 是一种潜在的治疗途径,特别是在EGFR突变的瘤中.

研究的目的:

审查目前关于EGFR-TKI在脑瘤中的应用的实验室和临床研究.
突出EGFR-TKI在控制瘤生长和改善患者治疗结果方面的潜力.
讨论与神经瘤学中的EGFR-TKI治疗相关的先进应用和挑战.

主要方法:

对现有的实验室和临床研究结果进行全面审查.
分析EGFR-TKI在原发性脑瘤和脑转移中的疗效.
研究先进的治疗策略,包括纳米配方和组合疗法.

主要成果:

EGFR-TKI在控制瘤进展和改善脑瘤的结果方面显示出潜力.
像纳米配方EGFR-TKI和组合疗法等先进的应用正在研究中.
仍然存在重大挑战,包括治疗副作用,抵抗机制和血脑屏障的透.

结论:

优化EGFR-TKI治疗需要通过个性化医学解决瘤异质性.
持续的研究对于完善EGFR-TKI治疗和提高脑瘤患者的存活率至关重要.
克服耐药性和增强药物输送是未来研究的关键领域.

关键词:

大脑转移是大脑的转移.临床研究的路径.欧洲农业基金的技术技能.质瘤是一种质瘤.临床前研究临床前研究

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.